Council Members in this Study Group: 855
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Leading institutions connect with members of this Study Group through GLG
Donald FlemingDivision Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC![]()
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed...
Instructor in Medicine
DANA-FARBER CANCER INSTITUTE, INC.![]()
Eric Jacobsen, MD, is Medical Oncologist and Hematologist in the Hematology and Oncology Department at the Dana-Farber Cancer Institute in Boston, MA. Dr. Jacobsen is a member of the lymphoma and bone marrow transplant divisions at Dana-Farber Cancer...
Associate Professor
Johns Hopkins University - CC![]()
William Matsui, MD, is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and the Johns Hopkins School of Medicine in Maryland, since July 2008. Dr. Matsui specializes in clinical and laboratory examination of hematological...
Brian AbbottMedical Director of Hematology
Big Sky Oncology![]()
Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology (Benefis Health System) and Sletten Cancer Institute in Great Falls, Montana. He is also Medical Director of the Palliative Medicine program. Dr. Abbott's specialties include...
Staff Physician
Ironwood Cancer & Research Center![]()
Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine...
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
Triple negative Breast Cancer Strategies
October 14, 2009
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer
Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
September 25, 2009
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with
Herceptin for Her2 + gastric cancer, If you can find one
September 25, 2009
Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com
Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer
REGORAFENIB joins a crowd of TKI's for RCC
September 25, 2009
Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com
RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved
December 11, 2007 | Atlanta
GLGi: Panel Review of the American Society of Hematology (ASH) 49th Annual MeetingLeading Experts in Oncologists who Treat Hematologic Malignancies (US) have not participated in any GLG webcasts.